All articles tagged with #zepbound
Eli Lilly's drug Zepbound, when combined with its immunology therapy Taltz, showed promise in reducing symptoms of psoriatic arthritis in obese patients, suggesting potential new uses for the weight loss drug, though its impact on prescribing patterns remains uncertain.
Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.
Eli Lilly's new obesity pill helps patients maintain weight loss after switching from injections like Wegovy and Zepbound, with promising trial results suggesting it could serve as a needle-free long-term treatment option, potentially capturing significant market share in the growing weight loss drug industry.
Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.
President Trump announced a deal with Eli Lilly and Novo Nordisk to expand coverage and lower prices for obesity drugs Wegovy and Zepbound, including Medicare coverage starting next year and phased price reductions for uninsured patients, aiming to improve access and affordability of these effective treatments.
Eli Lilly's obesity and diabetes drugs Mounjaro and Zepbound generated over $10 billion in Q3, fueling a booming market and a bidding war, with Novo Nordisk planning to acquire Metsera in a deal potentially worth up to $9 billion, highlighting intense competition in the GLP-1 receptor agonist space.
Eli Lilly's Q3 earnings surpassed expectations with $7.02 per share on $17.6 billion in sales, driven by strong sales of diabetes drug Mounjaro and weight-loss drug Zepbound, leading to an upward revision of annual guidance and a 3.9% rise in stock price.
Eli Lilly exceeded earnings and revenue estimates in Q3, driven by strong sales of weight loss drug Zepbound and diabetes treatment Mounjaro, leading to an upward revision of its full-year outlook and a 5% premarket stock increase.
Eli Lilly and Walmart have partnered to offer Zepbound, a weight loss drug, at discounted prices through retail locations and home delivery, expanding access and competing with rivals like Novo Nordisk amid regulatory and market pressures.
Eli Lilly has partnered with Walmart to distribute its weight-loss drug Zepbound at a lower cash-pay price, bypassing traditional insurance channels, with prices ranging from $350 to $500 per month, aiming to make the drug more accessible and competitive in the market.
A study suggests that weight loss drugs like Ozempic and Zepbound may provide additional benefits for psoriasis patients, including reduced risks of premature death, heart attacks, strokes, and substance abuse, potentially due to their anti-inflammatory effects and impact on mood and reward systems.
A real-world study shows that Novo Nordisk's Wegovy significantly outperforms Eli Lilly's Zepbound, reducing serious heart issues like stroke by over 50%.
Over 2,000 lawsuits have been filed against the makers of Ozempic and Zepbound, alleging severe side effects such as gastroparesis and intestinal issues, with regulatory updates and legal actions highlighting safety concerns about these GLP-1 receptor agonist drugs. The litigation is ongoing, with companies defending their safety profiles and the FDA issuing warnings about risks and unapproved formulations.
Charles, a 51-year-old man who struggled with weight loss after two surgeries, found success with the medication Zepbound, losing 117 pounds and improving his health markers, sleep, and activity levels, which allowed him to live a more active and fulfilling life.
Eli Lilly raised its 2025 sales and earnings guidance driven by strong demand for its weight loss and diabetes drugs Mounjaro and Zepbound, with second-quarter earnings surpassing estimates. The company also released trial data for its obesity pill, forglipron, which showed promising weight loss results but fell short of expectations, causing shares to drop. Despite robust revenue growth, Eli Lilly faces potential U.S. import tariffs and political pressure to lower drug prices.